Preparation and application of diagnosis and treatment integrated bottle-brush-shaped polymer nano delivery system
By designing bottle brush-shaped polymer nanomaterials with selective targeting capabilities, the problems of low targeting efficiency and great toxic side effects of existing tumor-targeting nanodrugs in vivo are solved, and efficient fluorescence imaging of various tumors is achieved and Treatment provides a wide range of diagnostic and therapeutic applications and provides scientific basis for subsequent design.
Patent Information
- Application Number
- CN202310820487.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-06-06
- Publication Date
- 2024-12-06
AI Technical Summary
Existing tumor-targeting nanodrugs are inefficient in targeting in vivo and have great toxic and side effects on normal tissues. Most studies only target specific tumor types and cannot achieve widespread clinical applications.
A type of bottle brush-like polymer nanomaterials with integrated diagnosis and treatment can be designed to achieve selective targeting of liver, lung and multiple tumors by adjusting their size and surface modification, using fluorescent backbone with π-conjugated structure and Nine polymer nanoparticles composed of side chains of different components have high fluorescence intensity and long-term accumulation capabilities, and are used for fluorescence imaging and treatment.
It realizes efficient targeting and long-term accumulation of multiple tumors, reduces the toxic side effects on normal tissues, provides a wide range of diagnostic and therapeutic applications, and provides science for the design of subsequent highly efficient tumor-targeted polymer carriers. in accordance with.
Smart Images

Figure CN119074962A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of fluorescence imaging of organs and tumors and tumor treatment, and in particular to the application of a type of integrated diagnosis and treatment bottle brush-shaped polymer nanomaterial. Background Art
[0003] Polymer drug carriers play a vital role in the treatment of diseases, especially tumors and various types of inflammation, specifically by improving the water solubility of hydrophobic drug molecules, improving drug metabolism kinetics, enhancing the targeting efficiency of drug delivery, and reducing toxic side effects on normal tissues and organs. Currently, the few nano-drug delivery systems that have been used in clinical tumor treatment (such as Doxil, Abraxane, Genexol PM, etc.) have disadvantages such as low efficacy and strong toxic side effects. Most of the nano-drug delivery systems with an average diameter greater than 10 nm reported so far still accumulate mainly in the liver after intravenous injection into mice, and the targeting effect on tumors is generally weak. How to design and prepare new drug delivery systems to improve their tumor-targeted delivery efficiency and reduce aggregation and residue in normal tissues and organs is not only a research hotspot in academia, but also a challenge faced by the pharmaceutical industry and the medical community.
[0004] The design principle of tumor-targeted nanomedicines is to rationally regulate the physical and chemical properties of nanomedicines (size, surface potential, hardness and shape, etc.), thereby improving their pharmacokinetics, enhancing the ability to penetrate tumor blood vessels and the permeability of tumor tissues, and achieving the purpose of improving the efficiency of tumor drug delivery. Existing studies have shown that the polymers of polyethylene glycol (PEG) and its oligoethylene glycol acrylate (OEGMA) modified on the surface of nanomedicines can significantly prolong the blood circulation time of drugs and increase their accumulation in tumor tissues. At the same time, recent studies have found that zwitterionic groups have similar functions, such as 3-[[2-(methacryloyloxy)ethyl]dimethylammonium]propionic acid (CBMA) and 2-methacryloyloxyethylphosphocholine (MPC). In general, current research still lacks a systematic and profound understanding of the complex environment and interactions of drug delivery systems in blood circulation and with animal tissues and organs, and cannot provide clear ideas for the design of efficient nanomedicines. In addition, because the cellular composition and functional state of the tumor microenvironment may vary greatly depending on the organ where the tumor occurs, the tumor stage, and the patient characteristics, most studies only focus on a certain tumor type and design drug delivery vehicles specifically for it, facing problems such as a narrow range of clinical applications.
[0005] The tumor-targeted functional polymer diagnostic and therapeutic nano-delivery system of the present invention integrates disease diagnosis and treatment functions, and has a wide range of uses in the development of new diagnostic and therapeutic reagents and drugs and medical applications. The polymer diagnostic and therapeutic system of the present invention can overcome the problem of separation of existing diagnostic and therapeutic systems, and provide a possible technical platform for realizing a new generation of precision medicine and follow-up treatment. It can not only improve the efficiency of diagnosis and treatment of tumors, but also can be used for the development of other diseases such as various inflammations and antiviral drugs and vaccines. Summary of the invention
[0006] One of the purposes of the present invention is to provide an application of a class of integrated diagnosis and treatment bottle brush polymer nanomaterials, which are composed of three fluorescent main chains with π-conjugated structures of different lengths (the number of repeating units is 7, 11, and 20) and three side chains with different components (copolymerized from OEGMA, CBMA, MPC and the anticancer drug CPT, respectively) (named OEGMA-7, 11, and 20 according to the main chain length and the main components of the side chains, CBMA-7, 11, and 20, and MPC-7, 11, and 20). The nanomaterials have high fluorescence intensity and carry anti-tumor drugs, can selectively target the liver, lungs and various tumors, and can accumulate in tumor tissues for a long time, so they can be used for fluorescence imaging and treatment of the liver, lungs and various tumors.
[0007] Preferably, MPC-modified bottlebrush polymer nanoparticles that can be targeted to the liver and used for fluorescence imaging are most enriched in the liver when the particle size is 25 nm.
[0008] Preferably, CBMA-modified bottlebrush polymer nanoparticles that can be targeted to the lungs and used for fluorescence imaging are most abundant in the lungs when the particle size is 17 nm.
[0009] Preferably, OEGMA-modified bottle-brush polymer nanoparticles that can target tumors and be used for fluorescence imaging are most enriched in tumor tissues when the particle size is 16 nm.
[0010] The OEGMA nanoparticles are suitable for treating breast cancer, pancreatic cancer, skin cancer, gastric cancer, lung cancer, colorectal cancer, bladder cancer, and head and neck tumors.
[0011] Preferably, the OEGMA nanoparticles are suitable for breast cancer and pancreatic cancer.
[0012] The technical solution adopted by the present invention is: The distribution of the polymer nanoparticles as fluorescent probes in organs and tumors at low doses.
[0013] The polymer nanoparticles are used as nanomedicines for distribution and metabolism in organs and tumors at high therapeutic doses.
[0014] The polymer nanoparticles have a tumor therapeutic effect.
[0015] The second purpose of the present invention is to study the effects of the size and surface modification of polymer nanoparticles on their biological behavior in vivo, and the technical solution adopted is: The effect of the size and surface modification of the polymer nanoparticles on their in vivo blood circulation half-life.
[0016] The effects of the size and surface modification of the polymer nanoparticles on their uptake by macrophages.
[0017] The effects of the size and surface modification of the polymer nanoparticles on their ability to penetrate tumor blood vessels.
[0018] The effects of the size and surface modification of the polymer nanoparticles on their tumor tissue penetration.
[0019] The third object of the present invention is to provide a method for preparing the polymer nanoparticles, and the nanoparticles obtained in one step can be applied to cells and living bodies. The specific technical solution is: The polymer is dissolved in an organic solvent and then dripped into water under ultrasonic conditions. The obtained nanoparticle solution is dialyzed in water to remove the organic solvent and obtain polymer nanoparticles.
[0020] The preferred method is: 5-100 mg of the above polymer is dissolved in 1-2 mL of an organic solvent, and then added dropwise to 5-10 mL of water under ultrasonic conditions. The resulting nanoparticle solution is dialyzed in water to remove the organic solvent to obtain polymer nanoparticles.
[0021] Preferably, the organic solvent is one or two of tetrahydrofuran (THF), ethanol, and N,N-dimethylformamide (DMF).
[0022] The beneficial effects of the present invention are: The present invention can achieve the selective accumulation of polymer nanoparticles in the liver and lungs by adjusting the size of the polymer and the modification of the surface groups; the prepared OEGMA-modified nanoparticles have good tumor targeting effects, and can achieve high-concentration accumulation and long-term retention in a variety of tumor models, including an in situ pancreatic cancer model, and have better tumor inhibition effects than camptothecin alone. Therefore, the polymer nanoparticles of the present invention can be used for organ-targeted tumor imaging and treatment.
[0023] This invention explains the effects of the size and surface modification of bottlebrush polymer nanoparticles on their tumor targeting and in vivo biological behaviors, such as pharmacokinetics, tumor vascular crossing and tumor tissue penetration, at a scale of 9-26 nm, providing a scientific basis for the subsequent design of efficient tumor-targeting polymer carriers.
[0024] In addition, the polymer of the present invention has good biocompatibility and has fewer side effects than single drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments will be briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope of the present invention.
[0026] Figure 1 is a schematic diagram of the structures of 9 bottle brush polymers in Example 1: OEGMA-7, 11, 20, CBMA-7, 11, 20, MPC-7, 11, 20; Figure 2 is the particle size of 9 polymer nanoparticles (100 μg / mL) in water in Comparative Example 1; Figure 3 is the surface potential of 9 polymer nanoparticles (100 μg / mL) in water in Comparative Example 1; Figure 4 is a transmission electron microscopy image of 9 polymer nanoparticles in Comparative Example 1; Figure 5 The organ and tumor fluorescence imaging images of the 9 polymer nanoparticles in the subcutaneous Panc02 pancreatic cancer of C57 mice and their average fluorescence intensity in each organ and tumor in Comparative Example 2 (dose is 2 mg / kg); Figure 6 Fluorescence imaging images of organs and tumors of OEGMA-11, MPC-7 and CBMA-20 polymer nanoparticles in subcutaneous 4T1 breast cancer of BALB / c mice and their average fluorescence intensity in each organ and tumor in Comparative Example 3 (dose of 2 mg / kg); Figure 7 Fluorescence imaging of organs and tumors of OEGMA-11 in subcutaneous 4T1 breast cancer of BALB / c mice and the average fluorescence intensity in each organ and tumor 1, 2, and 3 days after injection of OEGMA-11 polymer nanoparticles in Comparative Example 4 (dose of 40 mg / kg); Figure 8Fluorescence imaging of organs and tumors of OEGMA-11 in subcutaneous Panc02 pancreatic cancer of C57 mice and its average fluorescence intensity in each organ and tumor 1, 3, 5, 7, and 9 days after injection of OEGMA-11 polymer nanoparticles in Comparative Example 5 (dose of 30 mg / kg); Fig. 9 Organ and tumor fluorescence imaging of nanoparticles in the subcutaneous PANC-1 pancreas of BALB / c nude mice and their average fluorescence intensity within 21 days after injection of OEGMA-11 polymer nanoparticles in Comparative Example 6 (dose of 30 mg / kg); Fig.10 Organ and tumor fluorescence imaging images of OEGMA-11 polymer nanoparticles of different sizes in situ PANC-1 pancreatic tumors and their average fluorescence intensity in Comparative Example 7 (dose of 30 mg / kg); Fig.11 It is a graph showing the tumor inhibition growth of subcutaneous PANC-1 pancreatic cancer treated with PBS, OEGMA-11 and CPT in Comparative Example 8; Fig.12 The pharmacokinetic curves of the 9 polymer nanoparticles in Comparative Example 9 are as follows: the concentration of the nanoparticles in the blood changes over time; Fig.13 The confocal photographs of the polymer nanoparticles in RAW264.7 macrophages in Comparative Example 10 and the macrophage uptake results measured by flow cytometry; Fig.14 The comparison of the tumor vascular penetration ability of OEGMA-7, 11, 20 and MPC-7 polymer nanoparticles in the transwell device in comparative example 11; Fig.15 The penetration distribution diagram of OEGMA-11, 20 and MPC-7 in frozen sections of Panc02 pancreatic cancer in Comparative Example 12; Fig.16 This is a comparison chart of the serum biochemical constants of tumor-bearing mice treated with OEGMA-11, PBS and CPT in Comparative Example 13 and untreated normal mice. Implementation
[0027] As used herein: "Prepared from" is synonymous with "comprising." As used herein, the terms "comprising," "including," "having," "containing," or any other variation thereof, are intended to cover a non-exclusive inclusion. For example, a composition, process, method, article, or apparatus that comprises the listed elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to such composition, process, method, article, or apparatus.
[0028] The conjunction "consisting of excludes any unspecified element, step, or component. If used in a claim, this phrase renders the claim closed-ended so that it does not include materials other than those described, except for conventional impurities associated therewith. When the phrase "consisting of" appears in a clause of the body of a claim rather than immediately following the subject matter, it limits only the elements described in that clause; other elements are not excluded from the claim as a whole.
[0029] When an amount, concentration, or other value or parameter is expressed as a range, a preferred range, or a range defined by a series of upper preferred values and lower preferred values, this should be understood as specifically disclosing all ranges formed by any pairing of any range upper limit or preferred value with any range lower limit or preferred value, regardless of whether the range is disclosed separately. For example, when a range of "1 to 5" is disclosed, the described range should be interpreted as including ranges "1 to 4", "1 to 3", "1 to 2", "1 to 2 and 4 to 5", "1 to 3 and 5", etc. When a numerical range is described in this article, unless otherwise stated, the range is intended to include its end values and all integers and fractions within the range.
[0030] In these examples, parts and percentages are by mass unless otherwise indicated.
[0031] "Mass parts" refers to the basic unit of measurement for expressing the mass ratio of multiple components. 1 part can represent any unit mass, such as 1g or 2.689g. If we say that the mass parts of component A are a parts and the mass parts of component B are b parts, it means the ratio of the mass of component A to the mass of component B is a:b. Alternatively, it means that the mass of component A is aK and the mass of component B is bK (K is an arbitrary number, indicating a multiple factor). It should not be misunderstood that, unlike the mass parts, the sum of the mass parts of all components is not limited to 100 parts.
[0032] “And / or” is used to indicate that one or both of the stated situations may occur, for example, A and / or B includes (A and B) and (A or B). Example
[0033] The structure of polymer nanostructures Figure 1 As shown, the detailed preparation method of its aqueous solution nanoparticles is as follows: Preparation of OEGMA-7, 11 and 20 polymer nanoparticles: OEGMA-7 or 11 or 20 (50 mg) was dissolved in THF (1 mL), then quickly added dropwise to pure water (5 mL), and dialyzed in pure water to remove THF.
[0034] Preparation of MPC-7, 11 and 20 polymer nanoparticles: 10 mg of MPC series polymer was dissolved in a mixed solution of THF (1 mL) and ethanol (1:1), which was quickly injected into 5 mL of pure water with a syringe to form nanoparticles, and dialyzed in pure water to remove THF and ethanol; Preparation of CBMA-7, 11 and 20 polymer nanoparticles: 10 mg of CBMA series polymers were dissolved in 1 mL of a mixed solution of THF and DMF (1:1), which was quickly injected into 5 mL of pure water using a syringe to form nanoparticles, and then dialyzed in pure water to remove THF and DMF.
[0035] Comparative Example 1: like Figure 2 and Figure 3 As shown, the polymer nanoparticle solution (100 μg / mL) in Example 1 was measured for its particle size and surface potential by a Malvern laser particle size analyzer. The surface potentials of the MPC and CBMA series nanoparticles were approximately - 20.5 mV and + 9.3 mV, respectively. For the OEGMA series nanoparticles, the surface charge of OEGMA-11 was approximately - 7.0 mV and the surface charge of OEGMA-7, 20 was approximately - 16.4 mV; 4 μL of the polymer nanoparticle solution (100 μg / mL) in Example 1 was dropped onto the transmission electron microscope copper grid and left for 15 min. The solution was then blotted with filter paper and 4 μL of phosphotungstic acid solution was added for negative staining for 30 s. The solution was blotted with filter paper again and air-dried. The morphology of the nanoparticles was observed using a transmission electron microscope (TEM). Figure 4 As shown, the morphology of the polymer nanoparticles is spherical, among which the diameters of OEGMA-7, 11, 20 are 10.5, 16.1 and 23.0 nm, the diameters of MPC-7, 11, 20 are 14.1, 22.9 and 25.3 nm, and the diameters of CBMA-7, 11, 20 are 9.1, 13.2 and 16.8 nm.
[0036] Comparative Example 2: like Figure 5As shown, in the subcutaneous Panc02 pancreatic cancer model of C57 mice, each fluorescent polymer nanoparticle was injected into the mouse through the tail vein at a dose of 2 mg / kg. The mice were euthanized on the second day, and the tumors and major organs (brain, heart, liver, spleen, lungs and kidneys) were removed. Fluorescence imaging was performed using the PerkinElmer small animal imaging system and the mean fluorescence intensity (MFI) of the tissues was calculated. OEGMA series nanoparticles were mainly distributed in the liver and tumors, but the average fluorescence intensity of OEGMA-11 particles in the tumor site was 5.2 times that of the liver; MPC series nanoparticles were mainly distributed in the liver, and the accumulation in the tumor site gradually decreased with the increase in particle size; for CBMA series nanoparticles, they were basically not enriched in the tumor site, but with the increase in particle size, the enrichment in the spleen and lungs increased.
[0037] Comparative Example 3: like Figure 6 As shown in the figure, the subcutaneous 4T1 breast cancer model of BALB / c mice was used to verify the versatility of nanoparticles in targeting different tumor models. Fluorescent polymer nanoparticles at a dose of 2 mg / kg were injected into mice through the tail vein. The mice were euthanized on the second day, and the tumors and major organs (pancreas, heart, liver, spleen, lungs and kidneys) were removed for fluorescence imaging. The organ distribution of OEGMA-11 and MPC-7 in the 4T1 tumor model was basically the same as that in Panc02: OEGMA-11 was mainly distributed in the tumor, MPC-7 was mainly distributed in the liver, and CBMA-20 was mainly distributed in the liver and lungs, but the accumulation in the spleen was greatly reduced. The organ distribution in the two tumor models of 4T1 and Panc02 illustrates the superior fluorescence imaging ability of polymeric nanoparticles, and OEGMA-11 has good tumor targeting, MPC-20 specifically accumulates in the liver, and CBMA-20 can be enriched in the lungs.
[0038] Comparative Example 4: In the subcutaneous 4T1 tumor model of BALB / c mice, OEGMA-11 polymer nanoparticles at a dose of 40 mg / kg were injected into the mice through the tail vein. The mice were euthanized on days 1, 2, and 3, and the tumors and major organs (brain, pancreas, heart, liver, spleen, lung, and kidney) were removed for fluorescence imaging. Figure 7 As shown: Through nanoparticle fluorescence tracing, it was found that OEGMA-11 nanoparticles were mainly distributed in tumors and livers, and the accumulation concentration in tumors was much higher than that in livers; on day 1, nanoparticles accumulated rapidly in tumors, and then slowly increased on days 2 and 3; after calculation, the average fluorescence intensity of the tumor site on days 1, 2, and 3 was 13.23, 13.38, and 14.35 times that of the liver. These results demonstrate the superior targeting ability of OEGMA-11 nanoparticles in the subcutaneous 4T1 tumor model.
[0039] Comparative Example 5: In the subcutaneous Panc02 tumor model of C57 mice, OEGMA-11 polymer nanoparticles at a dose of 30 mg / kg were injected into the mice through the tail vein. The mice were euthanized on days 1, 3, 5, 7, and 9, and the tumors and major organs (pancreas, heart, liver, spleen, lung, and kidney) were removed for fluorescence imaging. Figure 8 As shown: OEGMA-11 nanoparticles are still mainly distributed in the tumor and liver, and the fluorescence in the tumor is still much higher than that in the liver; the concentration of nanoparticles in the tumor reaches the highest on the 5th day, and then slowly decreases. On the 9th day, the average fluorescence in the tumor is still more than 50% of the highest value on the 5th day, and the average fluorescence intensity ratio of OEGMA-11 nanoparticles in the tumor and liver is 11.10, 10.98, 11.82, 8.18 and 7.15 on the 1st, 3rd, 5th, 7th and 9th days, respectively.
[0040] Comparative Example 6: In the subcutaneous PANC-1 pancreatic cancer model of BALB / c nude mice, OEGMA-11 polymer nanoparticles at a dose of 30 mg / kg were injected into the mice through the tail vein, and the whole body of the mice was continuously imaged with fluorescence for 21 days. The mice were euthanized on the 2nd and 21st days, and the tumors and major organs (brain, pancreas, heart, liver, spleen, lungs and kidneys) were removed for fluorescence imaging. Fig. 9 As shown: In the 21 days after injection, the enrichment of nanoparticles first gradually increased in the tumor site, reaching the highest on the 4th day, and then slowly decreased; in the organ imaging on the 2nd and 21st days, OEGMA-11 was mainly distributed in the tumor and liver, and the fluorescence in the tumor site was still much higher than that in the liver, with ratios of 9.07 and 3.35, respectively.
[0041] Comparative Example 7: In an orthotopic PANC-1 pancreatic cancer model of BALB / c nude mice, OEGMA-11 polymer nanoparticles at a dose of 30 mg / kg were injected via the tail vein into tumors of approximately 25, 150, and 300 mm in size. 3 The mice were euthanized at 48 hours, and the major organs were removed and subjected to fluorescence imaging. Fig.10 As shown, for tumor size 300 mm 3 The whole body of the mouse was imaged at 6 hours. Fluorescence at the tumor site could be directly observed at the 6th hour, and gradually increased in the following time. Organs were removed and imaged, and it was found that in normal mice, OEGMA-11 nanoparticles were mainly evenly distributed in various organs, with the highest accumulation in the liver. When the tumor grew in the pancreas, it was found that the average fluorescence intensity of the nanoparticles in the growing tumor pancreas was about 2 times higher than that in the healthy pancreas, even if the in situ tumor was as small as 25 mm3 , the tumor could still be observed from the fluorescence images of the pancreas, demonstrating the superior targeting and fluorescence imaging capabilities of OEGMA-11 nanoparticles in the orthotopic PANC-1 model.
[0042] Comparative Example 8: In tumors 50 mm in size 3 In the subcutaneous PANC-1 tumor model, phosphate buffered saline (PBS), CPT and nanoparticles (OEGMA-11) were injected into mice through the tail vein, where the dose of CPT and CPT in OEGMA-11 was 10 mg / kg, and the administration cycle was 5 days, a total of 5 times, during which the changes in tumor size of the mice were monitored. Fig.11 As shown: On the 21st day after the end of administration, both CPT and OEGMA-11 showed anti-tumor effects compared with the PBS group. On the 70th day, the tumor sizes of the OEGMA-11 and CPT groups were 104 and 390 mm, respectively. 3 It is much smaller than the CPT group. The experimental results prove the good anti-tumor effect of OEGMA-11.
[0043] Comparative Example 9: Each nanoparticle at a dose of 2 mg / kg was injected into mice through the tail vein, and then a small amount of blood samples were taken at time points of 1 min, 1, 3, 6, 12, 24, and 48 h. The mean fluorescence intensity in the blood samples was measured by a small animal imaging system to obtain the metabolic curve of the drug in the blood, as shown in Fig.12 As shown: the blood half-lives of OEGMA-7, 11, and 20 are 1.9, 27.0, and 0.9 h, respectively, which are much longer than the common polyethylene glycol (PEG)-modified nanoparticles; the blood circulation time of the CBMA series nanoparticles is less than 1 h; and the half-lives of MPC-7, 11, and 20 nanoparticles are 4.9, 0.8, and 0.6 h, respectively.
[0044] Comparative Example 10: Mouse macrophages RAW264.5 were used to study the immune escape of nanoparticles. The nanoparticles were incubated with the cells, and after 4 h, the amount of nanoparticles taken up by the cells was characterized using fluorescence confocal microscopy and flow cytometry. The results are shown in Fig.13 As shown: The amount of OEGMA-11 taken up by macrophages is far less than that of other particles, proving that OEGMA-11 has the strongest immune escape ability and thus the longest blood circulation time.
[0045] Comparative Example 11: Mouse brain vascular cell line bEnd.3 was used to characterize the vascular penetration ability of nanoparticles. The in vitro simulation of blood vessels was achieved by using a Transwell device, which is divided into two layers. bEnd.3 cells were cultured on a polycarbonate membrane with micropores in the upper layer. The micropores only allow nanoparticles to pass through. When the cells in the upper layer are full, fluorescent nanoparticles are added to the upper chamber. The ability of nanoparticles to penetrate blood vessels can be obtained by measuring the average fluorescence in the culture medium of the lower chamber at different time points. The results are shown in 14: The fluorescence intensity of OEGMA-11 is about 6.7 times that of OEGMA-7, 20, and 3.1 times that of MPC-7, which proves the good tumor vascular penetration ability of OEGMA-11.
[0046] Comparative Example 12: Slice studies of tumor tissue can reveal the penetration of nanoparticles into tumor tissue. Fig.15 As shown: OEGMA-11 fluorescence is distributed in most areas of the tumor tissue, while OEGMA-20 and MPC-7 are basically distributed in the edge areas of the tumor tissue, which proves the good tumor tissue penetration ability of OEGMA-11.
[0047] Comparative Example 13: At the end of the experiment in Comparative Example 8, appropriate amounts of blood were taken from mice in each experimental group and normal mice, and serum was obtained after centrifugation. The concentrations of various biochemical indicators in the serum of mice were detected using a fully automatic biochemical analyzer (TP: total protein; ALB: albumin; GLOB: globulin; ALKP: alkaline phosphatase). Fig.16 As shown, there was no significant difference in TP, ALB, and GLOB between the serum of mice treated with PBS, CPT, and OEGMA-11 and those of normal mice. However, in the ALKP index, the mice in the OEGMA-11 group were closer to normal mice than those in the PBS and CPT groups, indicating that OEGMA-11 had better biocompatibility and fewer side effects.
[0048] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.
[0049] In addition, those skilled in the art will appreciate that, although some embodiments herein include certain features included in other embodiments but not other features, the combination of features of different embodiments is meant to be within the scope of the present invention and to form different embodiments. For example, in the above claims, any one of the claimed embodiments may be used in any combination. The information disclosed in this background technology section is intended only to deepen the understanding of the overall background technology of the present invention and should not be regarded as an admission or in any form of implication that the information constitutes prior art known to those skilled in the art.
Claims
1. Application of a bottle-brush polymer nano-delivery system for integrated diagnosis and treatment, It is characterized in that It is composed of 9 bottle-brush polymers, one or more of which form nanoparticles in aqueous solution with the function of targeting liver, lungs and tumors.
2. The nanoparticle according to claim 1, It is characterized in that One or more nanoparticles thereof have the functions of fluorescence imaging of liver, lung and tumor as well as tumor treatment.
3. The tumor targeting function of the nanoparticle according to claim 1, It is characterized in that The tumors used range from breast cancer, pancreatic cancer, skin cancer, gastric cancer, lung cancer, colorectal cancer, bladder cancer, and head and neck tumors.
4. The polymer nano delivery system according to claim 1, It is characterized in that The polymer structure includes a fluorescent main chain with a π-conjugated structure and a hydrophilic side chain containing an anticancer drug.
5. The polymer nano delivery system according to claim 1, It is characterized in that The side chain can carry a variety of anti-tumor small molecule drugs, and the drug is one or more of camptothecin, paclitaxel, and doxorubicin.
6. The polymer nanoparticles according to claim 1, It is characterized in that The preparation method comprises the following steps: dissolving the polymer in an organic solvent, slowly dropping the organic solution into water under ultrasonic conditions to form nanoparticles, and dialyzing the obtained solution to remove the organic solvent to obtain a polymer nanoparticle aqueous solution.
7. The method for preparing polymer nanoparticles according to claim 6, It is characterized in that The concentration of its aqueous solution is 0.1 mg / mL – 8 mg / mL.
8. The polymer nanoparticles according to claim 1, It is characterized in that Its particle size ranges from 9 nm – 26 nm.
9. The polymer nanoparticles with tumor targeting function according to claim 1 are used to study drug metabolism in mice. It is characterized in that When the dosage is 2 mg / kg, its blood circulation half-life ranges from 0 to 20 h.
10. The polymer nanoparticles with tumor targeting function according to claim 2, It is characterized in that Remains in tumor tissue for up to 21 days.
